Ambrisentan Tablets and Rifampin Intravenous
Determining the interaction of Ambrisentan Tablets and Rifampin Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Blood levels and effects of ambrisentan may increase during the first few days of treatment with rifAMPin. This can increase the risk of serious side effects such as liver damage, anemia, and fluid accumulation (particularly in the lungs). You may need more frequent monitoring by your doctor for several days if you have been using ambrisentan and are starting treatment with rifAMPin. Contact your doctor immediately if you experience fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. Also seek medical attention if you develop paleness, dizziness, fainting, swelling, unusual weight gain, difficulty breathing, and/or shortness of breath. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Acute, but not long-term, coadministration of rifampin increases the plasma concentrations of ambrisentan. Rifampin is an inhibitor of organic anion transporting polypeptide (OATP), a strong inducer of CYP450 3A4 and 2C19, and an inducer of P-glycoprotein and uridine diphosphate glucuronosyltransferases (UGTs), all of which have been shown in vitro to be involved in the metabolic clearance of ambrisentan. In healthy volunteers, acute coadministration (3 days) of rifampin 600 mg once daily with ambrisentan 10 mg once daily was associated with a transient 2-fold increase in ambrisentan systemic exposure (AUC). However, by day 7, rifampin had no clinically relevant effect on the AUC or Cmax of ambrisentan.
MANAGEMENT: Patients receiving ambrisentan therapy should be closely monitored when starting treatment with rifampin. Because ambrisentan is associated with dose-related hepatotoxicity, patients should be advised to notify their physician if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Patients should also be monitored for anemia, fluid retention, and pulmonary edema.
- Harrison B, Magee MH, Mandagere A, et al. "Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study." Clin Drug Investig 30 (2010): 875-85
- "Product Information. Letairis (ambrisentan)." Gilead Sciences, Foster City, CA.
Generic Name: ambrisentan
Brand name: Letairis
Synonyms: Ambrisentan
Generic Name: rifampin
Brand name: Rifadin, Rifadin IV, Rimactane
Synonyms: Rifampin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ambrisentan Tablets-Rifampin Oral, Intravenous
- Ambrisentan Tablets-Rifampin, Isoniazid, and Pyrazinamide
- Ambrisentan Tablets-Rifamycin
- Ambrisentan Tablets-Rifamycin Sodium
- Ambrisentan Tablets-Rifapentine
- Ambrisentan Tablets-Rifater
- Rifampin Intravenous-Amcinonide
- Rifampin Intravenous-Amcinonide Cream and Ointment
- Rifampin Intravenous-Amcinonide Lotion
- Rifampin Intravenous-Amcinonide Ointment
- Rifampin Intravenous-Amcinonide topical
- Rifampin Intravenous-Amcinonide Topical application